Salarius Pharmaceuticals Inc

Salarius Pharmaceuticals Inc Stock Forecast & Price Prediction

Live Salarius Pharmaceuticals Inc Stock (SLRX) Price
$1.56

0

Ratings

  • Buy 0
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$1.56

P/E Ratio

-0.06

Volume Traded Today

$30,600

Dividend

Dividends not available for SLRX

52 Week High/low

7.60/1.35

Salarius Pharmaceuticals Inc Market Cap

$2.5M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $SLRX ๐Ÿ›‘

Before you buy SLRX you'll want to see this list of ten stocks that have huge potential. Want to see if SLRX made the cut? Enter your email below

SLRX Summary

From what 0 stock analysts predict, the share price for Salarius Pharmaceuticals Inc (SLRX) might increase by 1566.67% in the next year. This is based on a 12-month average estimation for SLRX. Price targets go from $26 to $26. The majority of stock analysts believe SLRX is a sell. Please note analyst price targets are not guaranteed and could be missed completely.

SLRX Analyst Ratings

About 0 Wall Street analysts have assignedSLRX 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Salarius Pharmaceuticals Inc to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on SLRX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

SLRX stock forecast by analyst

These are the latest 20 analyst ratings of SLRX.

Analyst/Firm

Rating

Price Target

Change

Date

Michael King
HC Wainwright & Co.

Buy

$4

Maintains

Mar 11, 2022

HC Wainwright & Co.

Buy


Initiates

Aug 25, 2021

Benchmark

Speculative Buy


Initiates

Jun 16, 2020

Ladenburg Thalmann

Buy


Initiates

Apr 27, 2020

SLRX Company Information

  • Company Type: Clinical-stage biotechnology company
  • Focus: Developing treatments for cancers with unmet medical needs
  • Lead Candidate: Seclidemstat (SP-2577)
  • Clinical Trials: In Phase I/II trials for advanced solid tumors and Ewing sarcoma
  • Additional Product: SP-3164, a small molecular protein degrader for hematological and solid tumors
  • Strategic Partnerships:
    • University of Utah Research Foundation for exclusive patent rights for SP-2577
    • Cancer Prevention and Research Institute of Texas for product development activities
  • Location: Headquartered in Houston, Texas
SLRX
Salarius Pharmaceuticals Inc (SLRX)

When did it IPO

2015

Staff Count

2

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Mr. David J. Arthur M.B.A.

Market Cap

$2.5M

Salarius Pharmaceuticals Inc (SLRX) Financial Data

In 2023, SLRX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that SLRX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$5.2M

Revenue From 2021

$0

-100.00 %
From Previous Year

Revenue From 2022

$0

0.00 %
From Previous Year

Revenue From 2023

$0

0.00 %
From Previous Year
  • Revenue TTM $0
  • Operating Margin TTM 0.0%
  • Gross profit TTM $0
  • Return on assets TTM -54.0%
  • Return on equity TTM -119.8%
  • Profit Margin 0.0%
  • Book Value Per Share 3.71%
  • Market capitalisation $2.5M
  • Revenue for 2021 $0
  • Revenue for 2022 $0
  • Revenue for 2023 $0
  • EPS this year (TTM) $-8.73

Salarius Pharmaceuticals Inc (SLRX) Latest News

No news data available.

...

SLRX Frequently asked questions

The highest forecasted price for SLRX is $26 from at .

The lowest forecasted price for SLRX is $26 from from

The SLRX analyst ratings consensus are 0 buy ratings, 0 hold ratings, and 0 sell ratings.